Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin) (FLOX Regimen), Given Continuously or Intermittently, in Combination With Cetuximab (Erbitux), in First-line Treatment of Metastatic Colorectal Cancer. A Phase III Multicenter Trial.

NCT00145314 is registered in ClinicalTrials.gov with The Nordic Colorectal Cancer Biomodulation Group as lead sponsor.

NCT NCT00145314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00145314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin) (FLOX Regimen), Given Continuously or Intermittently, in Combination With Cetuximab (Erbitux), in First-line Treatment of Metastatic Colorectal Cancer. A Phase III Multicenter Trial.
Lead sponsor
The Nordic Colorectal Cancer Biomodulation Group
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2005
Completion date
August 31, 2010
Enrollment
571 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer